AMADIX

Amadix is a liquid biopsy company powered by AI, developing innovative non-invasive tests for early cancer detection in blood before the symptoms appear, to extend people’s lives.

Our AI platform integrates molecular biomarkers, imaging, and clinical data to train predictive models for early cancer detection.

PreveCol, our lead product for colorectal cancer, is already commercialized in Europe under the CE mark. It has also received the FDA Breakthrough Device Designation for its superior predictive capacity in detecting both colorectal cancer and precancerous lesions compared to existing alternatives.